ArticleBlood cancer journal2025

Long-term outcomes and clinical phenotypes associated with best response to low dose alemtuzumab in cutaneous T-cell lymphoma.

Cecilia Larocca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.